GRIT BIOTECHNOLOGY Trademark
Trademark Overview
On Thursday, July 7, 2022, a trademark application was filed for GRIT BIOTECHNOLOGY with the United States Patent and Trademark Office. The USPTO has given the GRIT BIOTECHNOLOGY trademark a serial number of 97492265. The federal status of this trademark filing is OPPOSITION PENDING as of Tuesday, November 7, 2023. This trademark is owned by Suzhou GRIT BIOTECHNOLOGY Co., Ltd.. The GRIT BIOTECHNOLOGY trademark is filed in the Pharmaceutical Products category with the following description:
Anti-cancer preparations, namely, biological preparations for developing T-cell based immunotherapy by building a series of proprietary tumor infiltrating lymphocyte; Anti-cancer preparations, namely, medical cell function activating drugs for developing T-cell based immunotherapy by building a series of proprietary tumor infiltrating lymphocyte; anti-cancer preparations in the nature of biological agents for treating cancer, namely, for treatment of solid tumor cancers by tumor infiltrating lymphocyte (TIL) therapy; Tumor suppressing agents for treating cancer, namely, for treatment of solid tumor cancers by TIL therapy
General Information
| Serial Number | 97492265 |
| Word Mark | GRIT BIOTECHNOLOGY |
| Filing Date | Thursday, July 7, 2022 |
| Status | 774 - OPPOSITION PENDING |
| Status Date | Tuesday, November 7, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 11, 2023 |
Trademark Statements
| Goods and Services | Anti-cancer preparations, namely, biological preparations for developing T-cell based immunotherapy by building a series of proprietary tumor infiltrating lymphocyte; Anti-cancer preparations, namely, medical cell function activating drugs for developing T-cell based immunotherapy by building a series of proprietary tumor infiltrating lymphocyte; anti-cancer preparations in the nature of biological agents for treating cancer, namely, for treatment of solid tumor cancers by tumor infiltrating lymphocyte (TIL) therapy; Tumor suppressing agents for treating cancer, namely, for treatment of solid tumor cancers by TIL therapy |
| Disclaimer with Predetermined Text | "BIOTECHNOLOGY" |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, July 12, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Suzhou GRIT BIOTECHNOLOGY Co., Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Suzhou 215121
CN |
| Party Name | Suzhou GRIT BIOTECHNOLOGY Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Suzhou 215121
CN |
Trademark Events
| Event Date | Event Description |
| Tuesday, November 7, 2023 | OPPOSITION INSTITUTED NO. 999999 |
| Friday, August 4, 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, July 11, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 11, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 21, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, June 5, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, May 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 11, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 11, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, April 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, April 27, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, April 27, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, April 21, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, July 12, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, July 11, 2022 | NEW APPLICATION ENTERED |
